SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CATX

Perspective Therapeutics, Inc. (New York Stock Exchange Arca:CATX)

US · Delayed Price · Currency is USD
Healthcare · Medical - Devices
$0.75-$0.03 (-3.85%)
 
Market cap
$91.0M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 10, 2005
Market Cap$91.03M-65.3%
Revenue (ttm)$177.00K-79.6%
Net Income-$122.91M-19.6%
EPS-$1.24+13.2%
Shares Out120.76M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,391,469
Open$0.76
Previous Close$0.78
Day's Range$0.74 - $0.79
52-Week Range$0.73 - $6.16
Beta1.99
AnalystsBuy
Price Target$7.50(+894.96%)
Earnings DateMar 15, 2027

About CATX

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

Address
2401 Elliott Avenue, Seattle, WA, 98121, US
Market Cap
91 million
Employees
165
Industrial Classification
Medical - Devices

Perspective Therapeutics, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
52nd Percentile Overall Score
CATX InsiderScore:69 / 99

Perspective Therapeutics, Inc. scored higher than 52% of companies evaluated by InsiderBuying, and ranked 38th out of 108 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Perspective Therapeutics, Inc. bought $175.4K of stock across 10 purchases in the last 90 days, the largest of them $37.9K.

Stake Increase

The average purchase added about 59% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.62M
Bought
$217.63K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy1 Hold0 SellAvg target $10.67 (+1315.5%)

5 firms rating CATX in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From CATX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-3.85%
5 Days
-19.81%
1 Month
-66.65%
6 Months
-81.06%
1 Year
-65.26%

$CATX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CATX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CATX's directors and management

Net Shares Purchased by Insiders−600k−300k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CATX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New CATX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CATX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CATX

VTIVanguard Morningstar Total Stock Market ETF$2.96M
IWMiShares Russell 2000 ETF$2.09M
VXFVanguard Extended Market ETF$1.14M
IWNiShares Russell 2000 Value ETF$764.87K
VTWOVanguard Russell 2000 ETF$694.85K
IBBiShares Biotechnology ETF$549.98K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CATX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
66.33
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
35

News check: BofA slashed price target 80% while Wedbush cut guidance; Q3 results reported amid analyst downgrades signal fundamental challenges.

Recent Insider Activity

Buys
12
Sells
7
Buy Value
$217.63K
Distinct Buyers
6

Insider Score Trend Over Time

+68.5 since Sep 3
0255075100Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 24.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Nov 12 — Insider Score 54.4Nov 13 — Insider Score 63.6Nov 14 — Insider Score 63.1Nov 15 — Insider Score 63.3Nov 16 — Insider Score 68.1Nov 17 — Insider Score 68.0Nov 18 — Insider Score 68.5Nov 19 — Insider Score 68.6Nov 20 — Insider Score 68.5Nov 21 — Insider Score 68.5Nov 22 — Insider Score 68.5Sep 3Sep 24Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.10%
IBBiShares Biotechnology ETF0.01%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.